Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 201–300 of 1,000

Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Léa Gauci, Émilie Lanoy, Stéphane Champiat, Caroline Caramella, Samy Ammari, Sandrine Aspeslagh, Andréa Varga, Capucine Baldini, Rastilav Bahleda, Anas Gazzah et al. · 2018 · Clinical Cancer Research
The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
Min Wang, Xiaoyang Zhai, Ji Li, Jingyuan Guan, Shuhui Xu, Yuying Li, Hui Zhu · 2021 · Frontiers in Immunology
Advances and prospects of biomarkers for immune checkpoint inhibitors
Hirohito Yamaguchi, Jung-Mao Hsu, Linlin Sun, Shao‐Chun Wang, Mien‐Chie Hung · 2024 · Cell Reports Medicine
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
Tiana Kordbacheh, Jamie Honeychurch, Fiona Helen Blackhall, Corinne Faivre Finn, Tim Illidge · 2017 · Annals of Oncology
Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
Zachary Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices · 2017 · Seminars in Immunology
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Gao, Zhifei, Bai, Yifeng, Lin, Anqi, Jiang, Aimin, Zhou, Chaozheng, Cheng, Quan, Liu, Zaoqu, Chen, Xin, Zhang, Jian, Luo, Peng · 2023 · Molecular Cancer
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Yuchu Xiang, Xudong Liu, Yifan Wang, Dawei Zheng, Qiuxing Meng, Lingling Jiang, Sha Yang, Sijia Zhang, Xin Zhang, Yan Liu et al. · 2024 · Frontiers in Immunology
Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark John Smyth, Kyohei Nakamura · 2020 · Journal of Hematology & Oncology
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, Rangarirai, Khalili, Neda, Razi, Sepideh, Keshavarz-Fathi, Mahsa, Rezaei, Nima · 2021 · Journal of Immunology Research
Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms
Huang, Mu-Yang, Jiang, Xiao-Ming, Wang, Bing-Lin, Sun, Yang, Lu, Jin-Jian · 2021 · Pharmacology & Therapeutics
Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
Md Amir Hossain, Guilai Liu, Beiying Dai, Yaxuan Si, Qitao Yang, Junaid Wazir, Lutz Birnbaumer, Yong Yang · 2020 · Medicinal Research Reviews
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Yuqing Zhang, Rolf A. Brekken · 2022 · Journal of Leukocyte Biology
Tim-3 expression and its role in hepatocellular carcinoma
Feifei Liu, Yanning Liu, Zhi Chen · 2018 · Journal of Hematology & Oncology
Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
Aviad Ben‐Shmuel, Guy Biber, Mira Barda‐Saad · 2020 · Frontiers in Immunology
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
Natalia Julia Sauer, Natalia Janicka, Wojciech Szlasa, Bartłomiej Skinderowicz, Katarzyna Kołodzińska, Wioletta Dwernicka, Małgorzata Oślizło, Julita Kulbacka, Vitalij Novickij, Katarzyna Karłowicz-Bodalska · 2023 · Cancer Immunology Immunotherapy
The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging
Benjamin M. Larimer, Emily Bloch, Sarah Nesti, Emily E. Austin, Eric Paul Wehrenberg-Klee, Genevieve Marie Boland, Umar Mahmood · 2018 · Clinical Cancer Research
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Yangzhi Qi, Baohui Liu, Qian Sun, Xiaoxing Xiong, Qianxue Chen · 2020 · Frontiers in Immunology
Mechanisms of Resistance to Immune Checkpoint Blockade
David Liu, Russell William Jenkins, Ryan Joseph Sullivan · 2018 · American Journal of Clinical Dermatology
Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy
Qin Fan, Zhipeng Chen, Chao Wang, Zhuang Liu · 2018 · Advanced Functional Materials
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, Kirat Kumar Ganguly, Malini Basu, Mrinal K. Ghosh · 2022 · Genes & Diseases
The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
Chloé Grasselly, Morgane Denis, Aurore Bourguignon, Nolan Talhi, Doriane Mathé, Anne Tourette, Laurent Serre, Lars Petter Jordheim, Eva Laure Matera, Charles Dumontet · 2018 · Frontiers in Immunology
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies
Yun Liu, Jianfeng Guo, Leaf Huang · 2020 · Theranostics
The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
Joji Nagasaki, Yosuke Togashi, Takeaki Sugawara, Makiko Itami, Nobuhiko Yamauchi, Junichiro Yuda, Masato Sugano, Yuuki Ohara, Yosuke Minami, Hirohisa Nakamae et al. · 2020 · Blood Advances
Mechanisms of resistance to immune checkpoint inhibitors
Joji Nagasaki, Takamasa Ishino, Yosuke Togashi · 2022 · Cancer Science
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Patrick Hall Lizotte, Elena V. Ivanova, Mark Magdi Awad, Robert E. Jones, Lauren Keogh, Hongye Liu, Ruben Dries, Christina G. Almonte, Grit Sophie Herter-Sprie, Abigail A. Santos et al. · 2016 · JCI Insight
Immune Checkpoint Inhibition in Head and Neck Cancer
Martin David Forster, Michael-John Devlin · 2018 · Frontiers in Oncology
Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer
Zihan Quan, Yang Yang, Hongmei Zheng, Yuting Zhan, Jiadi Luo, Yue Ning, Songqing Fan · 2022 · Journal of Cancer
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, Wen‐Fei Li, Lin Cong, Jialin Lu, Liyang Mo, Huizhen Liu, Siyi He, Chao Yu et al. · 2024 · Journal of Hematology & Oncology
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang · 2023 · Cancer Letters
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Xueping Wang, Fang Wang, Mengjun Zhong, Yosef Yarden, Liwu Fu · 2020 · Molecular Cancer
Advanced nanomedicine approaches applied for treatment of skin carcinoma
Harsimran Kaur, Prashant Kesharwani · 2021 · Journal of Controlled Release
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Andrew Warren Hahn, David Michael Gill, Sumanta Kumar Pal, Neeraj Agarwal · 2017 · Immunotherapy
Targeting phosphatidylserine for Cancer therapy: prospects and challenges
Wenguang Chang, Hongge Fa, Dandan Xiao, Jianxun Wang · 2020 · Theranostics
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao · 2017 · Journal of Hematology & Oncology
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
Catherine A. Sabatos-Peyton, James Timothy Nevin, Ansgar Brock, John D. Venable, Dewar J. Tan, Nasim Kassam, Fangmin Xu, John A. Taraszka, Luke David Wesemann, Thomas Pertel et al. · 2017 · OncoImmunology
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Pınar Ö. Eser, Pasi Antero Janne · 2017 · Pharmacology & Therapeutics
Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Zachary J. Brown, Su Jong Yu, Bernd Heinrich, Chi Ma, Qiong Fu, Milan Sandhu, David Agdashian, Qianfei Zhang, Firouzeh Korangy, Tim F. Greten · 2018 · Cancer Immunology Immunotherapy
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Isabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, Ioannis Psallidas, Markus Glatzer, David Rigau Comas, Philippe J. Astoul, Servet Bölükbas, Jeanette Boyd, Johan Coolen et al. · 2020 · European Journal of Cardio-Thoracic Surgery
Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more
Laura Chiossone, Margaux Vienne, Yann M. Kerdiles, Éric Vivier · 2017 · Seminars in Immunology
Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss
Yanhong Li, Jiayuan Zhang, Di Zhang, Xiaowu Hong, Tao Yu, Songcun Wang, Yuanyuan Xu, Hailan Piao, Weijie Yin, Min Yu et al. · 2017 · Science Signaling
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
Reem Saleh, Salman M. Toor, Sarah Khalaf, Eyad Elkord · 2019 · Vaccines
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
Shrestha, Ritu, Prithviraj, Prashanth, Anaka, Matthew, Bridle, Kim R., Crawford, Darrell H. G., Dhungel, Bijay, Steel, Jason C., Jayachandran, Aparna · 2018 · Frontiers in Oncology
Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit A. Fuhrman, Scott N. Gettinger, Roy S. Herbst, Kurt Alex Schalper, David L. Rimm · 2020 · Clinical Cancer Research
FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
Matthew Kraman, Mustapha Faroudi, Natalie L. Allen, Katarzyna Kmiecik, Daniel Gliddon, Claire J. Seal, Alexander Koers, Mateusz M. Wydro, Sarah Batey, Julia Winnewisser et al. · 2020 · Clinical Cancer Research
Clinical Insights Into Novel Immune Checkpoint Inhibitors
Jii Bum Lee, Sang‐Jun Ha, Hye Ryun Kim · 2021 · Frontiers in Pharmacology
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation
Ronan Joseph Kelly, Ali Hussainy Zaidi, Matthew A. Smith, Ashten N. Omstead, Juliann E. Kosovec, Daisuke Matsui, Samantha A. Martin, Christina M. DiCarlo, E. Day Werts, Jan F. Silverman et al. · 2017 · Annals of Surgery
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew David Hellmann, Nicoletta Bivi, Boris Calderón, Toshio Shimizu, Brant Delafontaine, Zhuqing Tina Liu, Anna M. Szpurka, Victoria Copeland, Frank Stephen Hodi, Sylvie Rottey et al. · 2021 · Clinical Cancer Research
Immunotherapy in Colorectal Cancer: Current and Future Strategies
Akira Ooki, Eiji Shinozaki, Kensei Yamaguchi · 2021 · Journal of the Anus Rectum and Colon
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Tao Shi, Yanyu Ma, Lingfeng Yu, Jiaxuan Jiang, Sunan Shen, Yayi Hou, Tingting Wang · 2018 · International Journal of Molecular Sciences
Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
Elizabeth Ann L. Enninga, Susan M. Harrington, Douglas J. Creedon, Rodrigo Ruano, Svetomir N. Markovic, Haidong Dong, Roxana Stefania Dronca · 2017 · American Journal of Reproductive Immunology
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani, Afshin Derakhshani, Omid Kooshkaki, Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Amir Baghbanzadeh, Hossein Safarpour, Ahad Mokhtarzadeh, Oronzo Brunetti, Simon C. Yue et al. · 2020 · International Journal of Molecular Sciences
Development of CAR T cells designed to improve antitumor efficacy and safety
Janneke E. Jaspers, Renier J. Brentjens · 2017 · Pharmacology & Therapeutics
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
Xiaoting Zhou, Yanghong Ni, Xiao Liang, Yi Lin, Biao An, Xiang He, Xia Zhao · 2022 · Frontiers in Immunology
Histone lactylation-driven B7-H3 expression promotes tumor immune evasion
Zhibo Ma, Jianming Yang, Wenlong Jia, Le Li, Yixin Li, Junjie Hu, Wei Luo, Ronghui Li, Dawei Ye, Peixiang Lan · 2025 · Theranostics
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
Saber İmani, Reyhaneh Farghadani, Ghazaal Roozitalab, Mazaher Maghsoudloo, Mahdieh Emadi, Atefeh Moradi, Behnaz Abedi, Parham Jabbarzadeh Kaboli · 2025 · Journal of Experimental & Clinical Cancer Research
Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches
Dongkui Song, Thomas B. Powles, Lei Shi, Lirong Zhang, Molly A. Ingersoll, Yong‐Jie Lu · 2019 · The Journal of Pathology
PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
Henning Zelba, Jens Bedke, Jörg Hennenlotter, Sven Mostböck, Markus Zettl, Thomas Zichner, Anoop Chandran, Arnulf Stenzl, Hans‐Georg Rammensee, Cécile Gouttefangeas · 2019 · Cancer Immunology Research
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
Victor C. Kok · 2020 · Frontiers in Oncology
Current Developments and Challenges of mRNA Vaccines
Jinjin Chen, Jianzhu Chen, Qiaobing Xu · 2022 · Annual Review of Biomedical Engineering
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, Giulia, Dias, Matheus Henrique, Bernards, René · 2021 · Cancers
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?
Hans‐Georg Eichler, Brigitte Bloechl‐Daum, Karl Broich, Paul Alexander Kyrle, Jillian Oderkirk, Guido Rasi, Rui Santos Ivo, Ad Schuurman, Thomas Senderovitz, Luke Slawomirski et al. · 2018 · Clinical Pharmacology & Therapeutics
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique Akhtar Javed, Asim Najmi, Waquar Ahsan, Khalid A. Zoghebi · 2024 · Frontiers in Immunology
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
Isobel Okoye, Michael Houghton, D. Lorne Tyrrell, Khaled Barakat, Shokrollah Elahi · 2017 · Frontiers in Immunology
New emerging targets in cancer immunotherapy: the role of TIM3
Alex Friedlaender, Alfredo Addeo, Giuseppe Luigi Banna · 2019 · ESMO Open
Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
Reem Saleh, Salman M. Toor, Varun Sasidharan Nair, Eyad Elkord · 2020 · Frontiers in Immunology
Advances in immunotherapy for glioblastoma multiforme
Ahmad Bakur Mahmoud, Reham Ajina, Sarah Aref, Manar Darwish, May A. Alsayb, Mustafa Taher, Shaker T. Alsharif, Anwar M. Hashem, Almohanad A. Alkayyal · 2022 · Frontiers in Immunology
NK cells to cure cancer
Clara Di Vito, Joanna Mikulak, Elisa Zaghi, Silvia Pesce, Emanuela Marcenaro, Domenico Mavilio · 2019 · Seminars in Immunology
Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
Paola Dama, Marshall Tang, Noreen C. Fulton, Justin Paul Kline, Hongtao Liu · 2019 · Journal for ImmunoTherapy of Cancer
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Amanda R. Dancsok, Nokitaka Setsu, Dongxia Gao, Jean‐Yves Blay, David Morgan Thomas, Robert G. Maki, Torsten O. Nielsen, Elizabeth G. Demicco · 2019 · Modern Pathology
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
Jianshu Wei, Can Luo, Yao Wang, Yelei Guo, Hanren Dai, Chuan Tong, Dongdong Ti, Zhiqiang Wu, Weidong Han · 2019 · Journal for ImmunoTherapy of Cancer
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Hui‐Ching Wang, Leong‐Perng Chan, Shih‐Feng Cho · 2019 · Frontiers in Oncology
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Cai Zhang, Yuxia Liu · 2020 · Frontiers in Immunology
Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy
Jaiwoo Lee, Quoc‐Viet Le, Geon Yang, Yu‐Kyoung Oh · 2019 · Biomaterials
Sono/Photodynamic Nanomedicine‐Elicited Cancer Immunotherapy
Yuce Li, Jun Xie, Wooram Um, Dong Gil You, Seunglee Kwon, Lianbin Zhang, Jintao Zhu, Jae Hyung Park · 2020 · Advanced Functional Materials
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
Adam Jacob Schoenfeld, Scott Joseph Antonia, Mark Magdi Awad, Enriqueta Felip, Justin F. Gainor, Scott N. Gettinger, Frank Stephen Hodi, Melissa Lynne Johnson, Natasha B. Leighl, Christine Marie Lovly et al. · 2021 · Annals of Oncology
Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
Li Zhu, Na Li, Fang Li, Zhi-Hua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu · 2016 · Medicine
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Pottayil G. Sasikumar, Murali Ramachandra · 2018 · BioDrugs
Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
Fakih, Marwan, Ouyang, Ching, Wang, Chongkai, Tu, Travis Yiwey, Gozo, Maricel C., Cho, May, Sy, Marvin, Longmate, Jeffrey A., Lee, Peter P. · 2019 · Journal of Clinical Investigation
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Anje Cauwels, Sandra Van Lint, Franciane Paul, Geneviève Garcin, Stefaan De Koker, Alexander Van Parys, Thomas Wueest, Sarah Gerlo, José Van der Heyden, Yann Bordat et al. · 2017 · Cancer Research
CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer
Paulino Tallón de Lara, Héctor Castañón, Marijne Vermeer, Nicolás Gonzalo Núñez, Karīna Siliņa, Bettina Sobottka, Joaquín Urdinez, Virginia Cecconi, Hideo Yagita∥, Farkhondeh Movahedian Attar et al. · 2021 · Nature Communications
Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells
Veronika Bachanová, Dhifaf Sarhan, Todd E. DeFor, Sarah Cooley, Angela Panoskaltsis‐Mortari, Bruce R. Blazar, Julie Curtsinger, Linda J. Burns, Daniel Jordan Weisdorf, Jeffrey S. Miller · 2017 · Cancer Immunology Immunotherapy
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer Methqal Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M. H. Towlerton, Edus Houston Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Alan Rizzieri, Mark G. Frattini et al. · 2018 · Clinical Cancer Research
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
Donghai Xiong, Yian Wang, Arun K. Singavi, Alexander Craig Mackinnon, Ben George, Ming You · 2018 · iScience
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
Jie Liu, Shuo Yang, Bihui Cao, Guangyu Zhou, Fengjuan Zhang, Yuan Wang, Rixin Wang, Lipeng Zhu, Ya Meng, Cong Hu et al. · 2021 · Journal of Hematology & Oncology
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them
Habashy, Karl John, Mansour, Rana, Moussalem, Charbel, Sawaya, Raymond, Massaad, Michel J. · 2022 · British Journal of Cancer
Immunotherapies for the Treatment of Uveal Melanoma—History and Future
Timo E. Schank, Jessica C. Hassel · 2019 · Cancers
The current state of immunotherapy for gliomas: an eye toward the future
Peter Edward Fecci, John Howard Sampson · 2019 · Journal of neurosurgery
Harnessing NK Cells for Cancer Treatment
Paola Minetto, Fabio Guolo, Silvia Pesce, Marco Greppi, Valentina Obino, Elisa Ferretti, Simona Sivori, Carlo Genova, Roberto Massimo Lemoli, Emanuela Marcenaro · 2019 · Frontiers in Immunology
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
Yoshie Kobayashi, Seung‐Oe Lim, Hirohito Yamaguchi · 2019 · Seminars in Cancer Biology
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf, Giuseppe Toffoli · 2020 · Drug Resistance Updates
Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity
Zhaoying Zhang, Caiyue Ren, Rong Xiao, Shuaiya Ma, Huimin Liu, Yutong Dou, Yu‐Chen Fan, Shuo Wang, Peng Zhan, Chengjiang Gao et al. · 2024 · Science Immunology
Immune regulation by Tim-3
Hridesh Banerjee, Larry Kane · 2018 · F1000Research
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence Marques Williams, Anne M. Noonan, Allan Tsung · 2020 · Gene Expression
Identifying key questions in the ecology and evolution of cancer
Antoine Marie Dujon, Athena Aktipis, Catherine Alix‐Panabières, Sarah R. Amend, Amy M. Boddy, Joel S. Brown, Jean‐Pascal Capp, James V. DeGregori, Paul W. Ewald, Robert A. Gatenby et al. · 2020 · Evolutionary Applications
Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
Shima Makaremi, Zahra Asadzadeh, Nima Hemmat, Amir Baghbanzadeh, Alessandro Sgambato, Farid Ghorbaninezhad, Hossein Safarpour, Antonella Argentiero, Oronzo Brunetti, Renato Bernardini et al. · 2021 · Biomedicines
Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance
Manshi Yang, Mengying Cui, Yang Sun, Shui Liu, Weibo Jiang · 2024 · Cell Communication and Signaling
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
Robert John Walsh, Ross Andrew Soo · 2020 · Therapeutic Advances in Medical Oncology
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
Tian Tian, Zhaoming Li · 2021 · Frontiers in Oncology
Emerging therapeutic agents for lung cancer
Bhagirathbhai Dholaria, William A. Hammond, Amanda J. Shreders, Yanyan Lou · 2016 · Journal of Hematology & Oncology
Effect of physicochemical properties on in vivo fate of nanoparticle-based cancer immunotherapies
Yongchao Wang, Jinjin Wang, Dandan Zhu, Yufei Wang, Guangchao Qing, Yuxuan Zhang, Xiaoxuan Liu, Xing‐Jie Liang · 2021 · Acta Pharmaceutica Sinica B